UBS Group’s Drugs Made In America Acquisition II Corp DMII Stock Holding History

UBS Group’s Portfolio DMII Stock Details DMII Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$446K	Buy	+44,735	New	+$446K	﹤0.01%	6160

Other funds holding DMII

Magnetar Financial Evanston, Illinois $9.84B AUM 190.64% 1-Year Est. Return

MMCAP International Grand Cayman, Cayman Islands $1.16B AUM 77.9% 1-Year Est. Return

KIM

Karpus Investment Management Pittsford, New York $3.21B AUM 6.83% 1-Year Est. Return

GCL

Glazer Capital LLC New York $4.71B AUM 81.93% 1-Year Est. Return

Healthcare of Ontario Pension Plan (HOOPP) Trust Fund Toronto, Ontario, Canada $62.2B AUM 31.35% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Hudson Bay Capital Management Stamford, Connecticut $29B AUM 30.2% 1-Year Est. Return

WAM

Wolverine Asset Management Chicago, Illinois $10.4B AUM 4.78% 1-Year Est. Return

PAMP

Polar Asset Management Partners Toronto, Ontario, Canada $5.01B AUM 35.27% 1-Year Est. Return

TCM

Tenor Capital Management New York $6.49B AUM 3.01% 1-Year Est. Return

UBS Group's DMII Position: Q1 2026 in Review

UBS Group opened a new position in Drugs Made In America Acquisition II Corp (DMII) in Q1 2026: 44,735 shares worth $446K. The stake represents ﹤0.01% of the portfolio and ranks #6160 among its holdings.

68 funds tracked by Wall St. Rank hold DMII as of Q1 2026.

UBS Group held 44,735 shares of Drugs Made In America Acquisition II Corp worth $446K as of Q1 2026.
Drugs Made In America Acquisition II Corp was a new UBS Group position in Q1 2026.
Drugs Made In America Acquisition II Corp made up ﹤0.01% of UBS Group's portfolio in Q1 2026, its #6160 holding.
68 funds tracked by Wall St. Rank held Drugs Made In America Acquisition II Corp as of Q1 2026.

Based on UBS Group's 13F filing for Q1 2026, filed 5 May 2026.